DPP1 (CTSC) Human shRNA Plasmid Kit (Locus ID 1075)

Specifications

Product Data
Product Name	DPP1 (CTSC) Human shRNA Plasmid Kit (Locus ID 1075)
Locus ID	1075
UniProt ID	P53634
Synonyms	CPPI; DPP-I; DPP1; DPPI; HMS; JP; JPD; PALS; PDON1; PLS
Vector	pGFP-C-shLenti
Format	Lentiviral plasmids
Kit Components	CTSC - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 1075). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
RefSeq	NM_001114173, NM_001814, NM_148170, NM_001814.1, NM_001814.2, NM_001814.3, NM_001814.4, NM_001814.5, NM_148170.1, NM_148170.2, NM_148170.3, NM_148170.4, NM_001114173.1, NM_001114173.2, BC023559, BC054028, BC100891, BC100892, BC100893, BC100894, BC107770, BC109386, BC110071, BC113850, BC113897, BC146692, BM997817, NM_148170.5, NM_001114173.3
Summary	This gene encodes a member of the peptidase C1 family and lysosomal cysteine proteinase that appears to be a central coordinator for activation of many serine proteinases in cells of the immune system. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate heavy and light chains that form a disulfide-linked dimer. A portion of the propeptide acts as an intramolecular chaperone for the folding and stabilization of the mature enzyme. This enzyme requires chloride ions for activity and can degrade glucagon. Defects in the encoded protein have been shown to be a cause of Papillon-Lefevre syndrome, an autosomal recessive disorder characterized by palmoplantar keratosis and periodontitis. [provided by RefSeq, Nov 2015]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.